Salarius Pharmaceuticals Inc [NASDAQ: SLRX] stock went on an upward path that rose over 69.48% on Tuesday, amounting to a one-week price increase of more than 68.39%.
Over the last 12 months, SLRX stock dropped by -68.93%. The one-year Salarius Pharmaceuticals Inc stock forecast points to a potential upside of 89.96. The average equity rating for SLRX stock is currently 3.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $1.57 million, with 0.60 million shares outstanding and 0.56 million shares in the current float. Compared to the average trading volume of 453.33K shares, SLRX stock reached a trading volume of 59957571 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Salarius Pharmaceuticals Inc [SLRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLRX shares is $26.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLRX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Salarius Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 27, 2020.
The Average True Range (ATR) for Salarius Pharmaceuticals Inc is set at 0.85 The Price to Book ratio for the last quarter was 0.39, with the Price to Cash per share for the same quarter was set at 7.28.
SLRX Stock Performance Analysis:
Salarius Pharmaceuticals Inc [SLRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 68.39. With this latest performance, SLRX shares gained by 3.57% in over the last four-week period, additionally sinking by -40.14% over the last 6 months – not to mention a drop of -68.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLRX stock in for the last two-week period is set at 52.30, with the RSI for the last a single of trading hit 56.61, and the three-weeks RSI is set at 49.47 for Salarius Pharmaceuticals Inc [SLRX]. The present Moving Average for the last 50 days of trading for this stock 3.0200, while it was recorded at 1.9900 for the last single week of trading, and 4.4500 for the last 200 days.
Insight into Salarius Pharmaceuticals Inc Fundamentals:
Salarius Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.91 and a Current Ratio set at 3.91.
Salarius Pharmaceuticals Inc [SLRX] Institutonal Ownership Details
The top three institutional holders of SLRX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in SLRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in SLRX stock with ownership which is approximately 5.1238%.
